Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: Review of a case series

Therapeutic Advances in Medical Oncology

Volumn 6, Issue 6, 2014, Pages 262-266

  Dooley, Andrew J ^a   Gupta, Avinash ^b   Bhattacharyya, Madhumita ^c   Middleton, Mark R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

intermittent; melanoma; resistance; toxicity; vemurafenib

Indexed keywords

CYCLOPENTOLATE; DABRAFENIB; DACARBAZINE; DEXAMETHASONE; IPILIMUMAB; TIMOLOL; VEMURAFENIB;

ACNE; ADULT; AGED; ANOREXIA; ARTHRALGIA; BONE METASTASIS; BRAF GENE; BRAIN METASTASIS; CASE STUDY; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; IRIDOCYCLITIS; LUNG METASTASIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; NAUSEA; NEPHROTOXICITY; ONCOGENE; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SKIN TOXICITY; VERY ELDERLY; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 84912113357     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834014548187     Document Type: Review

References (16)

1. Adams R. Meade A. Seymour M. Wilson R. Madi A. Fisher D. et al. (2011) Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12: 642-653.
2. Blum J. Dieras V. Lo Russo P. Horton J. Rutman O. Buzdar A. et al. (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768.
3. Chapman P. Hauschild A. Robert C. Haanen J. Ascierto P. Larkin J. et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
4. Das Thakur M. Salangsang F. Landman A. Sellers W. Pryer N. Levesque M. et al. (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255.
5. Davies H. Bignell G. Cox C. Stephens P. Edkins S. Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
6. Faivre S. Delbaldo C. Vera K. Robert C. Lozahic S. Lassau N. et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35.
7. Fecher L. Amaravadi R. Flaherty K. (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20: 183-189.
8. Flaherty K. Puzanov I. Kim K. Ribas A. McArthur G. Sosman J. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
9. Hauschild A. Grob J. Demidov L. Jouary T. Gutzmer R. Millward M. et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
10. Koop A. Satzger I. Alter M. Kapp A. Hauschild A. Gutzmer R. (2014) Intermittent B-Raf inhibitor therapy is a feasible option – report of a patient with metastatic melanoma. Br J Dermatol 170: 220-222.
11. Larkin J. Del Vecchio M. Ascierto P. Krajsova I. Schachter J. Neyns B. et al. (2014) Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15: 436-444.
12. Motzer R. Hutson T. Olsen M. Hudes G. Burke J. Edenfield W. et al. (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30: 1371-1377.
13. Motzer R. Hutson T. Tomczak P. Michaelson M. Bukowski R. Rixe O. et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
14. Naughton M. (2010) Evolution of capecitabine dosing in breast cancer. Clin Breast Cancer 10: 130-135.
15. Seghers A. Wilgenhof S. Lebbé C. Neyns B. (2012) Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 22: 466-472.
16. Sullivan R. Flaherty K. (2013) Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49: 1297-1304.